AbCellera Biologics Inc.ABCLEarnings & Financial Report
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Revenue
$5.0M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-45.0%
AbCellera Biologics Inc. Q4 FY2024 Financial Summary
AbCellera Biologics Inc. reported revenue of $5.0M (down 45.0% YoY) for Q4 FY2024, with a net profit of N/A (up 27.4% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $5.0M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2024 |
AbCellera Biologics Inc. Annual Revenue by Year
AbCellera Biologics Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $75.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $75.1M |
| 2024 | $28.8M |
| 2023 | $38.0M |
| 2022 | $485.4M |
AbCellera Biologics Inc. Quarterly Revenue & Net Profit History
AbCellera Biologics Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $44.9M | +788.4% | $-8.9M | -19.9% |
| Q3 FY2025 | $9.0M | +37.6% | $-57.1M | -637.8% |
| Q2 FY2025 | $17.1M | +133.3% | $-34.7M | -203.3% |
| Q1 FY2025 | $4.2M | -57.5% | $-45.6M | -1077.2% |
| Q4 FY2024 | $5.0M | -45.0% | N/A | N/A |
| Q3 FY2024 | $6.5M | -1.4% | $-51.1M | -785.4% |
| Q2 FY2024 | $7.3M | -27.2% | $-36.9M | -504.3% |
| Q1 FY2024 | $10.0M | -18.4% | $-40.6M | -408.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.0M | $7.3M | $6.5M | $5.0M | $4.2M | $17.1M | $9.0M | $44.9M |
| YoY Growth | -18.4% | -27.2% | -1.4% | -45.0% | -57.5% | 133.3% | 37.6% | 788.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.46B | $1.41B | $1.39B | $1.36B | $1.34B | $1.40B | $1.36B | $1.36B |
| Liabilities | $333.2M | $301.5M | $314.7M | $304.5M | $321.2M | $395.0M | $392.0M | $390.0M |
| Equity | $1.13B | $1.11B | $1.08B | $1.06B | $1.02B | $1.01B | $964.0M | $966.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-41.7M | $-30.0M | $-28.9M | $-108.6M | $-11.6M | $-32.4M | $-52.6M | $-34.7M |